WO1996019215A1 - Compositions of tocopherol and beta-carotene - Google Patents

Compositions of tocopherol and beta-carotene Download PDF

Info

Publication number
WO1996019215A1
WO1996019215A1 PCT/US1995/016769 US9516769W WO9619215A1 WO 1996019215 A1 WO1996019215 A1 WO 1996019215A1 US 9516769 W US9516769 W US 9516769W WO 9619215 A1 WO9619215 A1 WO 9619215A1
Authority
WO
WIPO (PCT)
Prior art keywords
carotene
natural
beta
tocopherol
vitamin
Prior art date
Application number
PCT/US1995/016769
Other languages
French (fr)
Inventor
James P. Clark
Manfred S. Dunker
Original Assignee
Henkel Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Corporation filed Critical Henkel Corporation
Priority to EP95944647A priority Critical patent/EP0793490A4/en
Priority to AU47419/96A priority patent/AU702831B2/en
Priority to JP8520012A priority patent/JPH10511355A/en
Publication of WO1996019215A1 publication Critical patent/WO1996019215A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to pharmaceutical compositions which exhibit a protective effect against the development of atherosclerosis.
  • These compositions comprise the combination of natural tocopherol and natural beta-carotene in a pharmaceutically acceptable carrier.
  • the present invention also includes within its scope methods of preventing the development of atherosclerosis and the resulting cardiovascular disease, e.g., coronary artery disease by administering an effective amount of the composition of the present invention to prevent atherosclerosis.
  • cardiovascular disease It is generally recognized that many factors contribute to the development of cardiovascular disease. These factors include, for example, smoking, obesity, hypertension, hyperlipidemia and hypercholesterolemia. Hyperlipidemia and hypercholesterolemia contribute to the accumulation of fatty substances on the arterial wall (atherosclerosis) resulting in narrowing of coronary blood vessels and the development of ischemic heart disease.
  • LDL low-density lipoprotein
  • Beta-carotene has also been suggested as useful in reducing vascular events in patients with chronic stable angina. See, Gaziano et al., "Beta Carotene Therapy for Chronic Stable Angina", Circulation. 82:111, Abstract No. 0796 (1990).
  • Tocopherols which occur in nature as alpha-tocopherol, beta-tocopherol, gamma-tocopherol and delta- tocopherol possess vitamin E activity. Chemically, they may be considered as having a "tocol" nucleus of the formula I:
  • R is(CH 2 ) 3 - CH(CH 2 ) 3 CH(CH 2 ) 3 CH(CH 3 ) 2
  • esters Both the free tocopherols and their esters are insoluble in water and soluble in fats and oil. Hence, they are also known as "fat-soluble vitamins. "
  • vitamin E While the precise role of vitamin E in human nutrition has not been clearly established, it has been suggested, that its deficiency may cause a variety of manifestations such as sterility, myocardial degeneration and necrosis of the liver.
  • the daily requirement is suggested to be about 30mg per day for a 70 kg adult human.
  • Carotenoids also occur in nature, mainly in plants. They are largely responsible for the yellow to red colors of many plants, particularly edible vegetables, such as carrots and squash. Chemically they are unsaturated, polyisoprene hydrocarbons. Over 500 carotenoids are known, e.g. , alpha, beta, and gamma carotene. The most widely used is beta-carotene because it is a precursor of vitamin A. The structural formula is described below (see VI). The daily requirement of vitamin A as suggested by National Research Council for maintenance of good health is 1,000 Retinol equivalents (RE) for males and 800 RE for females. (1,000 RE is equivalent to 5,000 International Unit.) The relation between carotene and vitamin A is 6 to 3.44 by weight of the respective pure compounds.
  • RE Retinol equivalents
  • compositions of polyol fatty acid polyesters such as sucrose octaoleate with vitamins, e.g., vitamin E.
  • U.S. Patent 4,005,196 discloses similar types of formulations, i.e., sucrose octacleate, with vitamins.
  • U.S. Patent 5,278,189 describes compositions of ascorbate with liprotein binders which include tocopherol and beta-carotene having the following structural formula:
  • Beta-carotene is a precursor of vitamin A. Thus, it is metabolized in the body to form vitamin A by cleavage of the double bond at the 15,15' position of compound VI.
  • vitamin A in human nutrition is known.
  • vitamin A deficiency leads to night blindness. It also plays an essential role in the growth and the formation of epithelial tissues.
  • beta-carotene acts as antioxidant in the formulation.
  • a primary object of the present invention is to provide compositions which exert a protective action against atherosclerosis and hence the prevention of the development of cardiovascular disease.
  • compositions comprise the combination of an effective antioxidant amount of natural tocopherol and a blend of natural carotene in a pharmaceutically acceptable carrier suitable for oral or parenteral administration.
  • compositions in which the protective effect of natural vitamin E has been enhanced by natural carotene blocks the oxidation of low-density lipoproteins in serum of mammals, including humans.
  • tocopherols which primarily comprise a mixture of compounds II, III and IV in the compositions are present in an effective antioxidant amount. Typically these compounds are present from about 50 to 1000
  • Natural tocotrienols and natural tocopherols are derived from vegetable oils.
  • Soy oil is the most widely used source. Sunflower, corn, peanut, rapeseed and cottonseed oils may also be used. Natural tocotrienol and natural tocopherols are very different from that produced by chemical synthesis, i.e., synthetic "vitamin E.”
  • vitamin E refers to both tocotrienols and tocopherols.
  • Synthetic vitamin E is a mixture of eight different stereoisomers, only one of which is molecularly equivalent to natural vitamin E. The other seven stereoisomers have a lower biological activity. The mammalian body prefers the natural stereoisomer.
  • Natural vitamin E is recognized as having 36 percent greater potency than synthetic vitamin E. Recent studies suggest that natural vitamin E is probably twice as effective as synthetic vitamin E.
  • Natural vitamin E also remains in the body much longer than synthetic vitamin E.
  • the seven synthetic stereoisomers are secreted into the bile and then into the intestine for removal from the body.
  • the natural vitamin E stereoisomer on the other hand, is returned to the bloodstream in the form of low density lipoproteins.
  • the natural carotene blend which will be described below is particularly preferred and is typically present from 5 to 50 mg per dosage unit.
  • the preferred naturally occurring carotene blend particularly suitable for the present invention has the following approximate composition:
  • Beta-carotene 85-90$ (approximately a 1: 1 mixture of cis- isomers and trans-isomers)
  • beta-carotene blends such as those isolated from palm oil, containing typically about 65 % all trans beta-carotene and 35 % alpha-carotene may be used in the present invention as well.
  • Lutein and zeaxanthin are naturally occurring substances from vegetable sources. Natural lycopene is found, for instance, in tomatoes. The natural enhance the biological effects of natural beta-carotene. For a fuller description of each of the foregoing compounds, please see Dictionary of Organic Compounds. Vol. 5.
  • Beta-carotene provitamin A
  • beta-carotene is readily metabolized by the body into vitamin A when required.
  • beta-carotene itself, independent of vitamin A activity.
  • the primary source of the beta-carotene is an algae named Dunaliella salina.
  • the algal cell functions just like an ordinary plant cell. It is photosynthetic, converting carbon dioxide from the atmosphere into cell material and to provide energy. This is done by the green chlorophyll in the cell which is normally not visible as it is masked by the intense orange color of the beta-carotene.
  • Natural beta-carotene from the algae comprises an approximately equal mixture of cis and trans isomers with the cis form of beta carotene being more soluble in oil than synthetic trans beta carotene.
  • Synthetic beta-carotene is derived from synthetic organic chemicals and is a crystalline form of beta-carotene, primarily the trans isomer (a molecular configuration). The synthetic form is not the focus of the present invention which is directed to natural source products because of the advantages associated with their use.
  • the synthetic crystals of beta-carotene are difficult to dissolve in organic chemical solvents, implying that the human body would have similar, or greater, difficulties in assimilating the compound.
  • the natural carotenoids are mixture of compounds. Those include beta- carotene, alpha-carotene, lutein, cryptoxanthin, zeaxanthin and lycopene.
  • the natural carotinoids are a mixture of cis and trans isomers while the synthetic carotenoids are all trans isomers.
  • Betatene natural mixed carotenoids
  • Betatene Ltd. is a registered trademark of Betatene Ltd. and is particularly useful in the practices of the present invention.
  • Betatene is a deep red suspension of natural mixed carotenoids in vegetable oil.
  • the mixed carotenoids are isolated from the sea algae Dunaliella salina.
  • Betatene, natural beta-carotene is soluble in oil to about 3.7% or about ten times the solubility of synthetic oil suspensions. This indicates a higher degree of bioavailability in the body.
  • Betatene 20% The carotenoid content of Betatene 20% is standardized to contain not less than 200 mg per gram of five naturally occurring carotenoids that are commonly found in various fruits, cruciferous, yellow, and dark green leafy vegetables.
  • the typical carotenoid distribution in Betatene 20% is as follows:
  • Beta-carotene 20% In addition to its role as an antioxidant, the beta-carotene provided by Betatene 20%, is a safe source of vitamin A, being converted to vitamin A within the body only as needed.
  • the oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms. Additionally, edible, non-toxic pharmaceutically acceptable stabilizers usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
  • compositions for oral administration may be in the form of tablets, including sustained release forms, lozenges, chewing gum, and capsules.
  • the soft gelatin capsule dosage form is most preferred. These dosage forms are prepared by those skilled in the art. Thus, for example, about 500 units of tocopherol and 25 mg of the beta-carotene blend as described above are blended with a sufficient amount of arachis oil to make about 450 mg. It is then dispensed into a soft gelatin capsule, the capsule is sealed by steam.

Abstract

A method for the prevention or treatment of atherosclerosis in a mammal, said method comprising administering an effective amount of natural tocopherol and natural carotene to prevent or treat atherosclerosis in a mammal in need of such prevention or treatment. A pharmaceutical composition for the prevention or treatment of atherosclerosis, which comprises an effective unit dosage amount of natural tocopherol and natural carotene to prevent or treat atherosclerosis and a pharmaceutically acceptable carrier therefor.

Description

COMPOSITIONS OF TOCOPHEROL
AND BETA-CAROTENE
Field of the Invention
The present invention relates to pharmaceutical compositions which exhibit a protective effect against the development of atherosclerosis. These compositions comprise the combination of natural tocopherol and natural beta-carotene in a pharmaceutically acceptable carrier. The present invention also includes within its scope methods of preventing the development of atherosclerosis and the resulting cardiovascular disease, e.g., coronary artery disease by administering an effective amount of the composition of the present invention to prevent atherosclerosis.
Background
It is generally recognized that many factors contribute to the development of cardiovascular disease. These factors include, for example, smoking, obesity, hypertension, hyperlipidemia and hypercholesterolemia. Hyperlipidemia and hypercholesterolemia contribute to the accumulation of fatty substances on the arterial wall (atherosclerosis) resulting in narrowing of coronary blood vessels and the development of ischemic heart disease.
In the articles "Vitamin E Consumption And The Risk Of Coronary Disease
In Women" by Stampfer et al., The New England Journal of Medicine. 328: 1444-9 (1993), and "Vitamin E Consumption And The Risk Of Coronary Heart Disease In
Men" by Rimm et al., The New England Journal of Medicine. 328: 1450-6 (1993), it was disclosed that oxidation of low-density lipoprotein (LDL) plays a role in atherosclerosis. Thus, the oxidation of LDL increases their incorporation into the arterial intima which is an essential step in atherogenesis. Consequently, a variety of dietary and drug regimen have been developed or proposed which would block the oxidative modification of LDL. These regimen usually include the ingestion of vitamin E alone.
Thus, in the two articles, cited above, the investigators studied the effect of administering vitamin E and the risk of coronary disease and observed that the use of vitamin E supplements in middle-aged women is associated with a reduced risk of coronary heart disease. Similarly, an association between a high intake of vitamin E and a lower risk of coronary heart disease was also observed in men.
In another study reported in Lancet. 342: 1379-84 (1993), it was observed that high beta-carotene intake reduce the risk of myocardial infarction. Beta- carotene has also been suggested as useful in reducing vascular events in patients with chronic stable angina. See, Gaziano et al., "Beta Carotene Therapy for Chronic Stable Angina", Circulation. 82:111, Abstract No. 0796 (1990).
Tocopherols which occur in nature as alpha-tocopherol, beta-tocopherol, gamma-tocopherol and delta- tocopherol possess vitamin E activity. Chemically, they may be considered as having a "tocol" nucleus of the formula I:
Figure imgf000004_0001
The naturally occurring alpha, beta, gamma, delta- tocopherols, respectively, differing from one another in the number or position of the methyl groups on the chroman ring of (I) have the following structural formulas II, III, IV, and V:
Figure imgf000004_0002
II
Figure imgf000005_0001
III
Figure imgf000005_0002
IV
Figure imgf000005_0003
CH3 CH3
/ wherein R is(CH2)3 - CH(CH2)3 CH(CH2)3 CH(CH3)2
These compounds possess antioxidative activity due to the presence of the phenolic hydroxy group at C-6 of the above compounds II, III, IV and V. These hydroxy groups are extremely susceptible to oxidation. Thus, they protect less susceptible compounds by breaking up the chain of oxidation reactions.
The presence of these phenolic hydroxy groups permit the formation of esters. Both the free tocopherols and their esters are insoluble in water and soluble in fats and oil. Hence, they are also known as "fat-soluble vitamins. "
While the precise role of vitamin E in human nutrition has not been clearly established, it has been suggested, that its deficiency may cause a variety of manifestations such as sterility, myocardial degeneration and necrosis of the liver.
The daily requirement is suggested to be about 30mg per day for a 70 kg adult human.
Carotenoids also occur in nature, mainly in plants. They are largely responsible for the yellow to red colors of many plants, particularly edible vegetables, such as carrots and squash. Chemically they are unsaturated, polyisoprene hydrocarbons. Over 500 carotenoids are known, e.g. , alpha, beta, and gamma carotene. The most widely used is beta-carotene because it is a precursor of vitamin A. The structural formula is described below (see VI). The daily requirement of vitamin A as suggested by National Research Council for maintenance of good health is 1,000 Retinol equivalents (RE) for males and 800 RE for females. (1,000 RE is equivalent to 5,000 International Unit.) The relation between carotene and vitamin A is 6 to 3.44 by weight of the respective pure compounds.
For a more detailed description of tocopherol and beta-carotene, see Bailey's Industrial Oil and Fat Products, pp. 69-98 (John Wiley & Sons, Inc., New York, New York, 1979).
Brief Description of the Prior Art
Tocopherols and vitamin A have been formulated in compositions with other vitamins as dietary supplements or with other compounds to control cholesterol. U.S. Patent 4,034,983 discloses compositions of polyol fatty acid polyesters such as sucrose octaoleate with vitamins, e.g., vitamin E. U.S. Patent 4,005,196 discloses similar types of formulations, i.e., sucrose octacleate, with vitamins. U.S. Patent 5,278,189 describes compositions of ascorbate with liprotein binders which include tocopherol and beta-carotene having the following structural formula:
Figure imgf000007_0001
VI
Beta-carotene is a precursor of vitamin A. Thus, it is metabolized in the body to form vitamin A by cleavage of the double bond at the 15,15' position of compound VI.
The role of vitamin A in human nutrition is known. For example, vitamin A deficiency leads to night blindness. It also plays an essential role in the growth and the formation of epithelial tissues. Like the tocopherols, beta-carotene acts as antioxidant in the formulation.
In a paper "Increased Preferential Absorption in Human Atherosclerotic Plaque with Oral Beta Carotene," Circulation. 1988, 78:338-344, it was reported that oral beta-carotene may influence selective ablation of atherosclerotic plaques. While the art recognizes the role of vitamin E in atherosclerosis as described in the aforementioned articles in The New England Journal of Medicine, and synthetic beta-carotene is available as "Solatene" from Hoffmann-LaRoche, Nutley, N.J., the prior art does not teach the protective or enhancing effect of natural tocopherols (vitamin E) on the cardiovascular system by combining the natural tocopherols with a particular blend of natural carotenes as described below. Such a combination is particularly beneficial in protecting the blood vessels from developing atherosclerosis and hence the prevention of cardiovascular disease.
Summary of the Invention
Accordingly, a primary object of the present invention is to provide compositions which exert a protective action against atherosclerosis and hence the prevention of the development of cardiovascular disease.
Broadly speaking, these compositions comprise the combination of an effective antioxidant amount of natural tocopherol and a blend of natural carotene in a pharmaceutically acceptable carrier suitable for oral or parenteral administration. These compositions in which the protective effect of natural vitamin E has been enhanced by natural carotene blocks the oxidation of low-density lipoproteins in serum of mammals, including humans.
Detailed Description of the
Preferred Embodiments of the Invention
According to the present invention tocopherols which primarily comprise a mixture of compounds II, III and IV in the compositions are present in an effective antioxidant amount. Typically these compounds are present from about 50 to 1000
International unit per dosage unit.
Natural tocotrienols and natural tocopherols are derived from vegetable oils.
Soy oil is the most widely used source. Sunflower, corn, peanut, rapeseed and cottonseed oils may also be used. Natural tocotrienol and natural tocopherols are very different from that produced by chemical synthesis, i.e., synthetic "vitamin E."
While the definition of vitamin E is not consistent, for the purposes of the present invention, vitamin E refers to both tocotrienols and tocopherols.
Synthetic vitamin E is a mixture of eight different stereoisomers, only one of which is molecularly equivalent to natural vitamin E. The other seven stereoisomers have a lower biological activity. The mammalian body prefers the natural stereoisomer.
Natural vitamin E is recognized as having 36 percent greater potency than synthetic vitamin E. Recent studies suggest that natural vitamin E is probably twice as effective as synthetic vitamin E.
Natural vitamin E also remains in the body much longer than synthetic vitamin E. The seven synthetic stereoisomers are secreted into the bile and then into the intestine for removal from the body. The natural vitamin E stereoisomer, on the other hand, is returned to the bloodstream in the form of low density lipoproteins.
Any natural tocopherol or tocotrienol, its ester or compounds convertible to either tocopherols or their esters are suitable for use in the practice of the present invention.
The prior art has failed to appreciate any benefit associated with the administration of tocotrienols and tocopherols to a mammal, including humans, to prevent the harmful effects of atherosclerosis. Further, the prior art has heretofore never recognized any benefit for such a method using natural tocotrienols and natural tocopherols.
With respect to the natural carotene component of the present invention, the natural carotene blend which will be described below is particularly preferred and is typically present from 5 to 50 mg per dosage unit.
The preferred naturally occurring carotene blend particularly suitable for the present invention has the following approximate composition:
Beta-carotene 85-90$ (approximately a 1: 1 mixture of cis- isomers and trans-isomers)
Alpha-carotene 10-5%
Lutein 2.5%
Zeaxanthin 2.5%
Other natural beta-carotene blends, such as those isolated from palm oil, containing typically about 65 % all trans beta-carotene and 35 % alpha-carotene may be used in the present invention as well.
Lutein and zeaxanthin are naturally occurring substances from vegetable sources. Natural lycopene is found, for instance, in tomatoes. The natural enhance the biological effects of natural beta-carotene. For a fuller description of each of the foregoing compounds, please see Dictionary of Organic Compounds. Vol. 5.
Beta-carotene, provitamin A, is readily metabolized by the body into vitamin A when required. There is also increasing evidence which suggests that there is a therapeutic benefit to beta-carotene itself, independent of vitamin A activity.
The primary source of the beta-carotene is an algae named Dunaliella salina.
The algal cell functions just like an ordinary plant cell. It is photosynthetic, converting carbon dioxide from the atmosphere into cell material and to provide energy. This is done by the green chlorophyll in the cell which is normally not visible as it is masked by the intense orange color of the beta-carotene.
Natural beta-carotene from the algae comprises an approximately equal mixture of cis and trans isomers with the cis form of beta carotene being more soluble in oil than synthetic trans beta carotene. Synthetic beta-carotene is derived from synthetic organic chemicals and is a crystalline form of beta-carotene, primarily the trans isomer (a molecular configuration). The synthetic form is not the focus of the present invention which is directed to natural source products because of the advantages associated with their use. The synthetic crystals of beta-carotene are difficult to dissolve in organic chemical solvents, implying that the human body would have similar, or greater, difficulties in assimilating the compound.
The natural carotenoids are mixture of compounds. Those include beta- carotene, alpha-carotene, lutein, cryptoxanthin, zeaxanthin and lycopene. The natural carotinoids are a mixture of cis and trans isomers while the synthetic carotenoids are all trans isomers.
Betatene, natural mixed carotenoids, is a registered trademark of Betatene Ltd. and is particularly useful in the practices of the present invention.
Betatene is a deep red suspension of natural mixed carotenoids in vegetable oil. The mixed carotenoids are isolated from the sea algae Dunaliella salina. Betatene, natural beta-carotene, is soluble in oil to about 3.7% or about ten times the solubility of synthetic oil suspensions. This indicates a higher degree of bioavailability in the body.
The carotenoid content of Betatene 20% is standardized to contain not less than 200 mg per gram of five naturally occurring carotenoids that are commonly found in various fruits, cruciferous, yellow, and dark green leafy vegetables. The typical carotenoid distribution in Betatene 20% is as follows:
200 mg/ gram beta-carotene 190,500 meg alpha-carotene 6,000 meg zeaxanthin 1 ,200 meg cryptoxanthin 1,400 meg lutein 900 meg
In addition to its role as an antioxidant, the beta-carotene provided by Betatene 20%, is a safe source of vitamin A, being converted to vitamin A within the body only as needed.
The oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms. Additionally, edible, non-toxic pharmaceutically acceptable stabilizers usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
The pharmaceutical compositions for oral administration may be in the form of tablets, including sustained release forms, lozenges, chewing gum, and capsules.
The soft gelatin capsule dosage form is most preferred. These dosage forms are prepared by those skilled in the art. Thus, for example, about 500 units of tocopherol and 25 mg of the beta-carotene blend as described above are blended with a sufficient amount of arachis oil to make about 450 mg. It is then dispensed into a soft gelatin capsule, the capsule is sealed by steam.

Claims

What is claimed is:
1. A method for the prevention or treatment of atherosclerosis in a mammal, said method comprising administering an effective amount of natural tocopherol and natural carotene to prevent or treat atherosclerosis to a mammal in need of such prevention or treatment.
2. The method according to claim 1 wherein approximately 50 to approximately 1000 international units of tocopherol and approximately 5 to approximately 50 mg of beta-carotene are administered.
3. The method according to claim 1 wherein said natural tocopherol and natural carotene are orally administered at least once per day.
4. A pharmaceutical composition for the prevention or treatment of atherosclerosis, which comprises an effective unit dosage amount of natural tocopherol and natural carotene to prevent or treat atherosclerosis and a pharmaceutically acceptable carrier therefor.
5. The composition according to claim 4 which comprises 50 to 1000 international units of tocopherol and 5 to 50 mg of beta-carotene per dosage unit.
6. The composition according to claim 4 wherein said carotene has the following composition:
Beta-carotene 85-90$ (approximately a 1 : 1 mixture of cis- isomers and trans-isomers)
Alpha-carotene 10-5 %
Lutein 2.5%
Zeaxanthin 2.5%
7. The composition according to claim 6 in which carotene isolated from palm oil containing about 65 % all trans beta-carotene and 35 % alpha-carotene.
8. The composition according to claim 6 further comprising lycopene.
9. A method for blocking the oxidation of LDL in serum which comprises contacting said serum with the composition as defined in claim 4.
PCT/US1995/016769 1994-12-22 1995-12-22 Compositions of tocopherol and beta-carotene WO1996019215A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95944647A EP0793490A4 (en) 1994-12-22 1995-12-22 Compositions of tocopherol and beta-carotene
AU47419/96A AU702831B2 (en) 1994-12-22 1995-12-22 Compositions of tocopherol and beta-carotene
JP8520012A JPH10511355A (en) 1994-12-22 1995-12-22 Composition of tocopherol and beta-carotene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36161594A 1994-12-22 1994-12-22
US08/361,615 1994-12-22

Publications (1)

Publication Number Publication Date
WO1996019215A1 true WO1996019215A1 (en) 1996-06-27

Family

ID=23422755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016769 WO1996019215A1 (en) 1994-12-22 1995-12-22 Compositions of tocopherol and beta-carotene

Country Status (4)

Country Link
EP (1) EP0793490A4 (en)
JP (1) JPH10511355A (en)
AU (1) AU702831B2 (en)
WO (1) WO1996019215A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040092A1 (en) * 1995-06-07 1996-12-19 The Howard Foundation Pharmaceutically active carotenoids
EP0793491A1 (en) * 1994-12-22 1997-09-10 Henkel Corporation Pharmaceutical compositions comprising lycopene
WO1998057622A1 (en) * 1997-06-19 1998-12-23 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and vitamin e for the prevention of ldl oxidation
WO1999018814A1 (en) * 1997-10-14 1999-04-22 Quest International B.V. Preparation for the enhancement of the antioxidant status of cells
EP0981969A1 (en) * 1998-08-26 2000-03-01 Basf Aktiengesellschaft Carotinoid compositions comprising a mixture of beta-carotene, lycopene and lutein
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
EP1140065A1 (en) * 1998-12-17 2001-10-10 Loma Linda University Medical Center Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
US6329432B2 (en) 1993-06-28 2001-12-11 The Howard Foundation Mesozeaxanthin formulations for treatment of retinal disorders
US6350776B1 (en) 1999-09-20 2002-02-26 Angelo Manfredo Azzi Method of treating proliferative disease with lycopene and alpha-tocopherol
US6515018B1 (en) 1997-06-19 2003-02-04 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and Vitamin E for the prevention of LDL oxidation
WO2005075575A1 (en) * 2004-02-10 2005-08-18 Nestec S.A. Compositions containing cis-isomers of a carotenoid compound and process
WO2006097090A1 (en) * 2005-03-17 2006-09-21 Schrezenmeir Juergen Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity
WO2006112906A1 (en) * 2005-04-13 2006-10-26 California Polytechnic State University Foundation Lycopene incorporation into egg yolks
WO2008017455A1 (en) * 2006-08-08 2008-02-14 Nestec S.A. Stable and bioavailable compositions of isomers of carotenoids for skin and hair
EP3401396A1 (en) * 2012-10-03 2018-11-14 Metabogen AB Treating or preventing atherosclerosis or associated diseases by beta-carotene

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057463C (en) * 1991-12-11 1998-10-27 David Rowland Vitamin/mineral composition
FR2714292B1 (en) * 1993-12-23 1996-02-02 Synthelabo Combination of DL-lysine acetylsalicylate and vitamin E.
IT1274734B (en) * 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
DK0845951T3 (en) * 1995-08-21 2002-05-27 Unilever Nv Antioxidant-containing food products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP0793490A4 *
THE LANCET, Vol. 342, issued 1993, KARDINAAL et al., "Antioxidants in Adipose Tissue and Risk of Myocardial Infarction: The Euramic Study", pages 1379-1384. *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329432B2 (en) 1993-06-28 2001-12-11 The Howard Foundation Mesozeaxanthin formulations for treatment of retinal disorders
EP0793491A1 (en) * 1994-12-22 1997-09-10 Henkel Corporation Pharmaceutical compositions comprising lycopene
EP0793491A4 (en) * 1994-12-22 2000-01-12 Henkel Corp Pharmaceutical compositions comprising lycopene
US6362221B1 (en) 1994-12-22 2002-03-26 Cognis Corporation Compositions containing natural lycopene and natural tocopherol
GB2301775B (en) * 1995-06-07 1999-08-04 Howard Foundation Treatment of age-related macular degeneration with carotenoids
WO1996040092A1 (en) * 1995-06-07 1996-12-19 The Howard Foundation Pharmaceutically active carotenoids
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
WO1998057622A1 (en) * 1997-06-19 1998-12-23 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and vitamin e for the prevention of ldl oxidation
US6515018B1 (en) 1997-06-19 2003-02-04 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and Vitamin E for the prevention of LDL oxidation
WO1999018814A1 (en) * 1997-10-14 1999-04-22 Quest International B.V. Preparation for the enhancement of the antioxidant status of cells
EP0981969A1 (en) * 1998-08-26 2000-03-01 Basf Aktiengesellschaft Carotinoid compositions comprising a mixture of beta-carotene, lycopene and lutein
CN1094326C (en) * 1998-08-26 2002-11-20 Basf公司 Carotenoid preparation having mixture of beta-carotene, lycopene and xanthophyll
US6261598B1 (en) 1998-08-26 2001-07-17 Basf Aktiengesellschaft Carotenoid formulations, comprising a mixture of B-carotens, lycopene and lutein
US6908943B2 (en) 1998-12-17 2005-06-21 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
EP1140065A4 (en) * 1998-12-17 2002-10-16 Univ Loma Linda Med Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
EP1140065A1 (en) * 1998-12-17 2001-10-10 Loma Linda University Medical Center Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
US6555575B2 (en) 1998-12-17 2003-04-29 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
US6350776B1 (en) 1999-09-20 2002-02-26 Angelo Manfredo Azzi Method of treating proliferative disease with lycopene and alpha-tocopherol
WO2005075575A1 (en) * 2004-02-10 2005-08-18 Nestec S.A. Compositions containing cis-isomers of a carotenoid compound and process
AU2005210014B2 (en) * 2004-02-10 2009-12-03 Nestec S.A. Compositions containing cis-isomers of a carotenoid compound and process
WO2006097090A1 (en) * 2005-03-17 2006-09-21 Schrezenmeir Juergen Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity
WO2006112906A1 (en) * 2005-04-13 2006-10-26 California Polytechnic State University Foundation Lycopene incorporation into egg yolks
WO2008017455A1 (en) * 2006-08-08 2008-02-14 Nestec S.A. Stable and bioavailable compositions of isomers of carotenoids for skin and hair
US9125430B2 (en) 2006-08-08 2015-09-08 Nestec S.A. Stable and bioavailable compositions of isomers of carotenoids for skin and hair
EP3401396A1 (en) * 2012-10-03 2018-11-14 Metabogen AB Treating or preventing atherosclerosis or associated diseases by beta-carotene

Also Published As

Publication number Publication date
AU702831B2 (en) 1999-03-04
EP0793490A1 (en) 1997-09-10
EP0793490A4 (en) 1999-12-15
JPH10511355A (en) 1998-11-04
AU4741996A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
US6362221B1 (en) Compositions containing natural lycopene and natural tocopherol
AU702831B2 (en) Compositions of tocopherol and beta-carotene
AU752468B2 (en) Lutein esters having high bioavailability
US6218436B1 (en) Pharmaceutically active carotenoids
EP1471898B1 (en) Lutein/zeaxanthin for glare protection
AU719671B2 (en) Pharmaceutically active carotenoids
WO1995000130A1 (en) Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
US20100233256A1 (en) Synergistic combinations for treating hypertension
US20110111055A1 (en) Nutritional supplements for relief of dry eye
JP5721740B2 (en) Combination of carotenoids and epilutein
JP2003516720A (en) Stable carotene-xanthophyll beadlet compositions and methods of use
KR20040078543A (en) Compositions for preventing human cancer and method of preventing human cancer
AU705467B2 (en) Pharmaceutical compositions comprising lycopene
EP0996431B1 (en) Synergistic compositions of lycopene and vitamin e for the prevention of ldl oxidation
US6515018B1 (en) Synergistic compositions for lycopene and Vitamin E for the prevention of LDL oxidation
US6358997B1 (en) Tocopherol and tocotrienol compositions
US6207187B1 (en) Compositions based on tocopherols
EP3456208B1 (en) Agent for improving carotenoid balance in blood
WO1996019218A1 (en) Tocopherol and tocotrienol compositions
Nogala-Kałucka Lipophilic vitamins
Rohmah et al. LIPOPHILIC BIOACTIVE-SECTION 1: VITAMIN A AND E
LAI FREDERICK KHACHIK FREDERICK B. ASKIN
MX2008007883A (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995944647

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 849975

Date of ref document: 19970820

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995944647

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995944647

Country of ref document: EP